• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Study applies human autoimmune encephalitis research to canine condition

October 4, 2019
dvm360, dvm360 November 2019, Volume 50, Issue 11

Veterinary researchers from North Carolina State University investigate whether antibodies play a role in etiology of poorly understood disease.

Results of a new study from North Carolina State University reveal that dogs suffer from the same type of autoimmune encephalitis as humans, according to a release from the College of Veterinary Medicine. The study's findings, just published in the Journal of Veterinary Internal Medicine, may lead to improved screening methods for diagnosis and possibly more effective treatments for canine encephalitis, the researchers say.

“Being able to show that dogs suffer from a specific autoimmune encephalitis is really a paradigm shift,” says Natasha Olby, MB, PhD, MRCVS, DACVIM, one of the study authors and professor of veterinary neurology at North Carolina State. “While treatment options will remain the same, we can now look for more antibody targets and perhaps be able to change the diagnosis from ‘unknown etiology' to a diagnosis by neuronal cell surface target.”

A hard-to-treat condition

Autoimmune encephalitis, an immune system reaction against the brain, is challenging to treat in dogs. In fact, veterinary neurologists have been unable to differentiate between the large numbers of non-infectious cases, referring to them as “meningoencephalitis of unknown etiology.”

“When we diagnose encephalitis based on MRI and spinal tap, we run infectious disease testing. If we rule out infection (which accounts for only a small portion of these cases), we are left with a diagnosis of meningoencephalitis of unknown etiology. This is an umbrella term for autoimmune encephalitis, and we treat these dogs with immunosuppression,” Dr. Olby says.

In human medicine, researchers have a better grasp on autoimmune encephalitis. This is largely because of the discovery of antibodies to different surface proteins on neurons found in people with encephalitis. N-methyl-D-aspartate (NMDA) receptor encephalitis, in which there are antibodies to the excitatory NMDA receptor, is the most common. Now even more of these surface protein targets have been identified, each associated with a different form of autoimmune encephalitis, according to the release.

Advertisement

“In reality, there are likely to be many different forms of autoimmune encephalitis in which the immune system is reacting to different targets within the brain. Currently, we are unable to distinguish these in the living patient. While we treat all the cases with immunosuppression, better categorization of the different forms of encephalitis might enable us to predict prognosis better and fine-tune treatment for different diseases,” Dr. Olby says.

Screening for antibodies

Dr. Olby and her team used a test that screens for antibodies against six different neuronal surface targets involved with autoimmune encephalitis in humans to test the cerebrospinal fluid (CSF) from dogs with encephalitis. Human and canine genes for these targets are practically identical, which is why a human test works effectively for dogs, the release indicates.

“The test contains cells that express the human target proteins at high levels and if there are antibodies to these targets in the CSF, they will bind to the cells and we can visualize them with a fluorescent tag,” Dr. Olby says.

Finally, the researchers screened CSF banked from 32 dogs with both inflammatory and non-inflammatory neurological disease.

Study results may lead to improved treatment options

Nineteen of the 32 dogs screened were diagnosed with inflammatory disease, of which three were positive for antibodies to the NMDA receptor target. All three dogs responded well to immunosuppressive therapy, the researchers say.

“Being able to categorize the disease more accurately may give both dogs and humans more options for treatments in the future,” Dr. Olby says.

The researchers conclude that “further evaluation of the prevalence and clinical relevance of CSF and serum antibodies to neuronal cell surface antigens is warranted.”

download issueDownload Issue: dvm360 November 2019

Related Content:

MedicalNeurologyBreaking NewsEducationdvm360 November 2019
Drug for acute onset of canine pancreatitis is launched on the US market
Drug for acute onset of canine pancreatitis is launched on the US market
PetSmart Charites will gift $6 million to UC Davis with endowed chair
PetSmart Charites will gift $6 million to UC Davis with endowed chair
Diagnostics for a thoracic trauma patient
Diagnostics for a thoracic trauma patient

Advertisement

Latest News

Drug for acute onset of canine pancreatitis is launched on the US market

New Automatic 2-in-1 Pet Feeder and Water Dispenser launched

PetHub launches AI tools for pet owners

Prairie dog pups emerge from underground at Maryland Zoo

View More Latest News
Advertisement